Caris Life Sciences Q2 Revenue Jumps 45%, Raises 2026 Guidance
CAI sits 32% above its 52-week low of $14.19 on elevated volume (1.9× avg).
Summary
Caris Life Sciences delivered a strong Q2 with revenue up 45% to $263.7M, driven by a 55% surge in molecular profiling services. Net loss nearly vanished, shrinking to $0.6M from $71.8M a year ago, while gross margin expanded 500 bps to 68%. Management raised full-year 2026 revenue guidance to $1.03-$1.04B, implying 27-28% growth, and reaffirmed ~20% clinical therapy selection volume growth. This follows a 78.8% revenue jump in Q1 and a recent $1.2B credit facility, underscoring accelerating commercial traction. The results handily beat the prior quarter's pace and signal the company is approaching sustained profitability.
At the time of this announcement, CAI was trading at $18.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.7B. The 52-week trading range was $14.19 to $42.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.